Chorioallantoic Membrane Tumor Model for Evaluating Oncolytic Viruses.

Area of Science:

• Oncology
• Virology
• Preclinical models

Background:

• Oncolytic viruses show promise as anticancer agents, but clinical efficacy requires improvement.
• Current in vivo preclinical models (syngeneic, xenograft) are labor-intensive and time-consuming for evaluating numerous modified viruses.
• Overcoming delivery barriers is crucial for enhancing oncolytic virus effectiveness against primary tumors and metastases.

Purpose of the Study:

• To establish and validate the chicken chorioallantoic membrane (CAM) assay as a high-throughput in vivo model for oncolytic virus evaluation.
• To provide a platform for screening modified oncolytic viruses before extensive animal studies.
• To assess the feasibility of the CAM model for analyzing virus-host interactions, biodistribution, and tumor targeting.

Main Methods:

• Establishment, characterization, and optimization of the CAM assay for oncolytic virus studies.
• Utilized human adenovirus type 5 (HAdV-5) for model validation.
• Demonstrated both intratumoral and intravenous administration routes within the CAM model.

Main Results:

• The CAM assay serves as a quick, low-cost, high-throughput in vivo tumor model system.
• The model successfully facilitated the analysis of oncolytic virus administration, biodistribution, and targeting.
• Human adenovirus type 5 demonstrated feasibility within the CAM model, suggesting broad applicability.

Conclusions:

• The chicken chorioallantoic membrane (CAM) assay is a valuable tool for the in vivo evaluation of oncolytic viruses.
• This model system accelerates the screening of modified viruses, aiding in the development of novel anticancer therapies.
• The CAM assay supports the analysis of critical parameters like virus delivery, biodistribution, and host interactions.